- Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic.
- The Company’s tissue repair and restoration products are proprietary and backed by medical research showing greater effectiveness than traditional competing solutions and approaches.
- Vericel has only scratched the surface of tapping into a $2B+ addressable market for its products and growth looks be accelerating coming out of the summer 2020 COVID lockdowns.
- Management has indicated that significant margin expansion iscoming, as the company is able to leverage a largely fixed cost base as salesgrowth resumes.
For further details see:
Vericel: Biotech Leader In Engineered Tissue Solutions With Rapid Growth & Profitability